Inflow of new injectors per year |
θ |
- |
Fit to PWID population size |
HCV incidence among PWID per 100 person years (2008 unless stated otherwise) |
Vary infection rate, λ, to fit. |
|
Estimated from NESI data(23) and prison survey(9). See section 3.2 of the supplementary details. HCV incidences are sampled from the distributions obtained by a bootstrapping method to estimate the 95% confidence intervals. |
Recent community PWID (<5 years injecting) |
|
11.9–40.6 |
Non-recent community PWID (>5yrs injecting) |
|
4.8–19.5 |
Incarcerated PWID with OST (2010/11) |
|
0.9–10.2 |
Incidence amongst incarcerated PWID in absence of OST is sampled from lognormal(2.3,0.6) which is truncated to the 95% confidence interval (4.5,31.8) found in previous prison survey before OST was introduced(14). |
Incarcerated PWID without OST |
|
4.5–31.8 |
HCV antibody prevalence |
|
|
|
Community PWID (2008) |
|
49.7–54.0% |
(23) |
Incarcerated PWID (2010/11) |
|
51.0–55.9% |
(9) |
Proportion of new infections that spontaneously clear |
α |
0.22–0.29 |
(30) Sampled from uniform distribution |
Annual PWID treatments in community (Average rate per 1000 Community PWID) |
Φc
|
|
(27, 28) |
2008–2014 |
|
66–103 (4.4–6.8) |
|
2015–2030 |
|
103 (6.8) |
|
Annual PWID treatments in Prison (Average rate per 1000 Incarcerated PWID) |
Φp
|
|
(27, 28) |
2008–2014 |
|
4–16 (2.6–10.4) |
|
2015–2030 |
|
Varied |
|
Sustained viral response |
π |
|
|
PEG-IFN/RBV in community |
|
60–66% |
(29) Sampled from uniform distribution |
PEG-IFN/RBV in prison |
|
55–66% |
(29) Sampled from uniform distribution |
DAAs (2015–2030) |
|
90% |
(16) |
Percentage of incarcerated PWID with sentences: |
|
|
|
>16 weeks |
ε |
39.9–46.0% |
Estimated from the prison survey. Both sampled from normal distribution |
>12 weeks |
ε2
|
57.3–63.3% |
Increased risk amongst recently released PWID (<6 months since release) |
η |
0.97–5.46 |
Estimated from NESI data (see section 3.1 of the supplementary details). Sampled from lognormal distribution |